INTRODUCTION
The mammalian cell membrane is coated with a dense thicket of glycans-complex sugar chains that are post-translationally attached to most membrane proteins. These glycans serve as a primary point of contact between the cell and the rest of the world, mediating cell interactions with small molecules, microorganisms, and even other cells. 1 As a result, changes in glycosylation are often indicative of irregularities in the cellular machinery, and have previously been correlated with a number of human diseases-most famously, cancer. Several decades of research have now firmly established aberrant glycosylation as one of the hallmarks of cancer. 2, 3 Glycans have been shown to mediate many cancer-related processes, [4] [5] [6] [7] [8] and cell membrane glycans, in particular, play primary roles in tumorigenesis, 9-11 metastatic colonization, 12, 13 and chemotherapeutic drug resistance. 14, 15 Numerous studies on the human serum glycome (i.e. from secreted glycoproteins) have already identified potential biomarkers for multiple cancer types. [16] [17] [18] [19] However, the cell membrane glycome remains a largely untapped source of potential biomarkers, due in large part to the difficulty of isolating cell membrane glycoproteins from those found in the cytoplasm, nucleoplasm, or cellular organelles. Previous studies on cell membrane glycosylation have been limited in scope, relying largely on affinity interactions (either lectin-or antibody-based) to detect specific glycosylation motifs or epitopes. 12, [20] [21] [22] Unfortunately, because these affinity interactions typically target only terminal monosaccharides, the analytical data gleaned from affinity-based studies is often inconclusive or subject to extensive interpretation. Additionally, due to the extraordinary structural heterogeneity of glycans, many glycan structures simply cannot be detected (or distinguished) by currently-available affinity-based methods.
Recently-developed LC/MS-based methods of glycomic profiling, in contrast, offer direct and comprehensive access to cell membrane glycosylation. An et al recently developed and validated a method to isolate and enrich cell membrane N-glycans, enabling quantitative, reproducible, and (most importantly) LC/MS-compatible analysis. 23 LC/MS compatibility is crucial to glycomic analyses, particularly when complex, structurally heterogenous analytes (such as cell membrane glycans) are involved. Over 200 glycosyltransferases and glycosidases work in concert to decorate proteins with glycosylation, and even slight perturbations in this delicate balance can result in widespread changes. 24 Glycomic profiling of these changes can be an extremely sensitive indicator of disease progression; however, detailed analytical methods are necessary in order to accurately capture the full structural complexity of the glycome. LC/MS fits this requirement exceedingly well, providing two-dimensional separation of complex glycan mixtures according to accurate mass, size, and three-dimensional conformation.
Nano-LC/MS methods for separation and profiling of N-glycans have recently been developed and optimized by Hua et al. 16 These methods utilize chip-based porous graphitized carbon (PGC) nano-LC to separate complex glycan mixtures in a structure-sensitive manner prior to high resolution, accurate mass TOF-MS analysis. In tests on serum N-glycans, the optimized PGC nano-LC/TOF-MS platform provided detailed and comprehensive glycan identification, miniscule sample consumption, and dramatically increased sensitivity over previous MALDI-MS or high-flow LC/MS methods. 25 The present study combines cell membrane N-glycan enrichment procedures with detailed nano-LC/MS glycan profiling to provide the first comprehensive survey of cancer cell Nglycosylation. Cell membrane N-glycan profiles were obtained for fifteen different cell lines isolated from ovarian, breast, lung, cervical, and lymphatic cancer patients (as well as one non- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 cancerous fibrocystic breast cell line 
METHODS

Cell culture
Cell lines (Hs-578T, ZR-75-1, MCF-7, MCF-7/HER2, MCF10A, Raji, Ramos, NCI-H929, BCBL-1, ES-2, NCI-H358, A549, C-33A, CaSki, and HeLa) were obtained from ATCC. Cell cultures were performed using the ATCC-recommended growth media, subcultivation ratios, and medium renewal interval (available online at www.atcc.org).
During cell harvest, in order to preserve membrane glycoprotein integrity, cells were scraped rather than enzymatically lifted. For each cell sample, approximately 10 million cells were counted and collected. Duplicate samples were collected from the lymphoma (Raji; Ramos; NCI-H929; BCBL-1), cervical carcinoma (33A; CaSki; HeLa), and lung carcinoma (NCI-H358; A549) cell cultures; however, due to cell growth limitations, only single samples were collected from the breast (Hs-578T; ZR-75-1; MCF-7; MCF-7/HER2; MCF10A) and ovarian (ES-2) cell cultures. 
Plasma membrane extraction
Isolation of the plasma membrane was performed according to optimized procedures published by An et al. 23 Briefly, cells were suspended a homogenization buffer consisting of 0.25 M sucrose; 20 mM HEPES-KOH, pH 7.4; and 1:100 protease inhibitor mixture (EMD Millipore) prior to sonication. Cell lysates were ultracentrifuged at 1,000 g and 200,000 g to remove the nuclear and cytosolic fractions, respectively. Supernatants, consisting of enriched plasma membranes, were collected for glycan extraction.
N-glycan release and enrichment
Enzymatic release and solid-phase extraction of N-glycans were performed according to optimized procedures published by Kronewitter et al. 26 Briefly, membrane glycoproteins were denatured by rapid thermal cycling (25-100 °C) in an aqueous solution of 100 mM ammonium bicarbonate and 5 mM dithiothreitol. Next, 2.0 µL (or 1000 U) of peptide N-glycosidase F (New England Biolabs) were added and the mixture was incubated in a microwave reactor (CEM Corporation) for 10 minutes at 20 watts. Following the addition of 800 µL of cold ethanol, the mixture was chilled at -80 °C for 1 hour, then centrifuged in order to precipitate out the deglycosylated proteins. The glycan-rich supernatant fraction was collected and dried in vacuo.
Graphitized carbon solid-phase extraction was performed using an automated liquid handler (Gilson). Graphitized carbon cartridges (150 mg, 4.0 mL, Grace Davison) were washed with 80% acetonitrile / 0.10% trifluoroacetic acid (v/v) in water, then conditioned with pure water.
Aqueous N-glycan solutions were loaded onto the cartridges and washed with pure water to remove salts and buffer. Membrane N-glycans were eluted with sequential addition of 10% acetonitrile, 20% acetonitrile, and 40% acetonitrile / 0.05% trifluoroacetic acid (v/v) in water.
Samples were dried in vacuo.
Nano-LC/MS analysis and data processing
MS analysis was performed according to optimized procedures published by Hua et al. 16 Briefly, aqueous glycan solutions were injected by autosampler onto a chip-mounted nano-LC column 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 protonated ion, and all associated isotopologues). Thus, each individual ECC peak could be taken to represent the total ion count associated with a single distinct compound.
Each ECC peak was matched by accurate mass to a comprehensive library of all possible complex, hybrid, and high mannose glycan compositions based on known biosynthetic pathways and glycosylation patterns. 27, 28 Deconvoluted masses of each ECC peak were compared against theoretical glycan masses using a mass error tolerance of 20 ppm and a false discovery rate of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 applicable, the results of duplicate analyses were averaged. Previous studies have already validated the quantitative reproducibility of the cell membrane glycan extraction procedure as well as the PGC nano-LC/MS platform, enabling rapid profiling and comparison of individual glycan abundances. 16, 23 In addition to individual glycan profiling, overarching differences in cell membrane glycosylation can be detected through glycan class profiling. In Figure 1a , the glycan 
Differentiation of cancerous and non-cancerous cells
When radiological imaging techniques detect the presence of tumors or lesions within a patient, doctors must determine whether these abnormal masses are malignant (cancerous), or benign (non-cancerous). While histological characteristics can often indicate whether a tumor is currently benign or cancerous, molecular markers can potentially increase accuracy, and might To demonstrate the utility of cell membrane glycan profiling towards tumor diagnosis, glycan class profiles (Figure 2) were compared amongst four cancerous breast cell lines (Hs-578T, ZR-75-1, MCF-7, and MCF-7/HER2) and one non-cancerous breast cell line (MCF-10A).
All four cancerous cell lines originated from ductal breast carcinomas, whereas the non- 
Identification of cancer cell origin and type
Once doctors identify a cancerous tumor in a patient, one of the first steps towards devising an effective treatment is to determine the primary origin of the cancer. However, in approximately 3% of patients, the primary cancer site is never found. Often, these cancers are poorly differentiated, lacking key morphological features that can be used to identify the origin of more developed cells. [32] [33] [34] To make matters worse, poorly differentiated (high grade) cancers are typically the most aggressive, growing faster and spreading more rapidly than well-differentiated (low grade) cancers. 35 Lymphomas, which originate from the lymphatic system, commonly exhibit poor differentiation. 32, 36 In Figure 3 The incredibly high correlation of the Raji and Ramos cell lines (Figure 4) is quite significant biologically, because both of these cell lines derive from Burkitt's lymphoma patients.
However, the patients were different from each other in almost every other respect-Raji was isolated from an African in Nigeria, whereas Ramos was isolated from a Caucasian in the United States; Raji represents the endemic form of Burkitt's lymphoma, whereas Ramos represents the spontaneous form; Raji was isolated in the early 1960s, whereas Ramos was isolated more than a decade later. 37, 38 Yet, despite these differences, the individual glycan signals isolated from the Raji and Ramos cell membranes exhibit a startlingly high correlation (R = 0.974)-suggesting that, in at least some cases, glycosylation patterns can be linked to specific cancer variants even in spite of confounding genetic and environmental factors.
Distinguishing between epithelial carcinomas from different organs
Identification of a primary cancer site enables doctors to focus diagnostic testing and treatment, significantly improving a patient's chances for survival; however, radiological observations are often obfuscated by metastatic tumors. To make matters worse, carcinomas, which derive from a variety of epithelial tissues, often exhibit very similar histologic and biochemical characteristics, even when they originate from different organs. This similarity creates significant problems when doctors need to differentiate between primary and metastatic carcinomas.
Cell membrane glycan profiling, however, may help determine the origin of a carcinoma. To demonstrate this concept, several cervical and lung carcinoma cell lines were selected for analysis. Cervical carcinomas commonly metastasize to the lung, forcing doctors to differentiate between primary lung carcinomas and metastatic cervical carcinomas prior to treatment. 39 Therefore, in Figure 5 , N-glycan profiles were compared amongst two lung carcinoma cell lines (NCI-H358 and A549) and three cervical carcinoma cell lines (C-33A, CaSki, and HeLa). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 cell line, C-33A, is more intriguing-clustering actually reveals that cervical carcinoma cell line C-33A is more closely related to lung carcinoma cell lines NCI-H358 and A549 than to its fellow cervical carcinoma cell lines CaSki and HeLa. C-33A is rather unique amongst cervical carcinoma cell lines in that it is completely negative for human papillomavirus (HPV) DNA, whereas most cervical carcinomas (and cell lines derived therefrom) harbor significant quantities of HPV DNA. 40 For example, cervical carcinoma cell lines CaSki and HeLa are both HPVpositive and display highly correlated membrane glycosylation profiles (Figure S2) , presumably due to mutual HPV-induced carcinogenesis. The cluster containing HPV-negative cervical carcinoma cell line C-33A and the two lung carcinoma cell lines, therefore, likely represents a grouping of cell lines for which carcinogenesis occurred due to largely genetic rather than environmental (e.g. viral) factors.
To distinguish amongst these individual cell lines, more detailed glycan profiling techniques were applied. Individual glycan species, identified and tracked by mass spectrometry, were employed as markers to differentiate amongst cell lines C-33A (cervical carcinoma), NCI-H358
(lung carcinoma), and A549 (lung carcinoma). Cervical carcinoma cell line C-33A was readily distinguished by elevated levels of glycans Man4GlcNAc2 and Man3GlcNAc2, which were present at 7-fold and 4-fold abundance, respectively, relative to the two lung carcinoma cell lines (Figure 6a ). Lung carcinoma cell line NCI-H358, in turn, was readily distinguished from lung carcinoma cell line A549 by 6-fold elevated levels of glycans Man3GlcNAc2Fuc, Man3GlcNAc3Fuc, and Man3GlcNAc4Fuc (Figure 6b) . Interestingly, all five marker glycans are biosynthetically related, each differing from the next by only one monosaccharide.
Additionally, all represent relatively early steps in the glycan biosynthesis process, suggesting a lower degree of differentiation-one of the hallmarks of cancer glycosylation. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60
CONCLUSION
We have demonstrated for the first time direct analysis of cancer cell membrane N-glycans by nano-LC/MS, revealing stark differences in the glycosylation of different cell types. The platform is not only quantitatively reproducible, but also highly sensitive, with a large dynamic range. 16 Additionally, porous graphitized carbon nano-LC provides structure-sensitive separation of isomeric glycans. 41 Though structural elucidation was not pursued in the present study, the platform's demonstrated structural separation capabilities may be easily coupled to tandem MS fragmentation for future glycan structure studies. 31, 42, 43 The observation of such stark differences in the membrane N-glycosylation patterns of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 indicating the wide applicability of the membrane fractionation and LC/MS analysis procedures.
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